United Therapeutics Corp. (UTHR) PT Raised to $525 at Cantor Fitzgerald

Cantor Fitzgerald analyst Olivia Brayer raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $525.00 (from $405.00) while maintaining a Overweight rating.

The analyst commented, "We're raising our PT to $525/share (from $405) on a best-case TETON-2 readout. We're now giving Tyvaso a 90% POS in IPF. We model Tyvaso peak IPF sales at >$4.3B (vs. $2.5B prior and $2.6B consensus, VisibleAlpha). Consensus was only $1B pre-TETON-2. The market is still only pricing in $2.0B-2.5B peak IPF sales. Success in IPF (the TETON studies) completely reshapes UTHR's growth trajectory."

You May Also Be Interested In

• Bicara Therapeutics Inc (BCAX) PT Raised to $39 at BTIG
• On Holding AG (ONON) PT Lowered to $60 at BTIG
• Freedom Broker Downgrades Critical Metals (CRML) to Hold